• 7 July 2010
  • News
  • By

Poised for a leap in Indian market

12
Merck

Head: Dr Marek Dziki (CEO)
Business: Supplier of pharmaceutical and chemical products
Start-up Year:2005
Address: Lloyds Centre Point, 1st Floor, Appasaheb Marathe Marg, Prabhadevi, Mumbai-400025, Maharashtra
Tel: +91-22-67944309
Fax: +91-22-64944309
Website: www.merck.co.in

Life Sciences Business
(in Rs Crore)

Rs 97* Crore
* BioSpectrum estimates
In India, Merck's chemical products offering fulfills the needs of both industrial production as well as research
Merck, through its manufacturing facility in Goa, is the only manufacturer of Guaiazulene, TDS and Oxynex ST

In India, Merck is represented by the companies and production sites including Merck India, Merck Specialities and its manufacturing site in Goa.

Merck Limited (formerly E Merck Limited) was set up in India in 1967; which was the first Merck Group company in Asia. It went public in 1981 and was the first Merck Group company to do so. Merck Specialities is the Indian sales organization of the global Merck Group of Darmstadt, Germany. It supplies the Indian market with high-quality pharma and chemical products. Established in 2005, Merck India is wholly-owned by Merck KgaA.

In India, Merck's chemical products offering fulfills the needs of both industrial production as well as research. Major products in chemicals include reagents, analytical chromatography, food and water analysis products, microbiology and hygiene products.

Merck, through its manufacturing facility at Goa, is the only manufacturer of Guaiazulene, Thiamine Disulfide (TDS) and Oxynex ST, in addition to being the largest manufacturer of vitamin E in India. Its new dehydrated culture media plant in India is the first plant outside Germany.

Last year, Merck KGaA announced the acquisition of Bangalore Genei (India) Private Limited (BGIP) by its wholly-owned subsidiary in India, Merck Specialities, from the Sanmar Group.

BGIP is located in Bangalore and specializes in the development, production, marketing and sales of products for proteomic and genomic research. With more than 100 employees, the company generated total revenues of Rs 20.20 crore in fiscal year 2008-09.

Commenting about the acquisition, Christina Shasserre, Global Head of Merck's bioscience business, says, “BGIP's leadership in the Indian academic market, a segment with high growth potential, will ideally complement our existing customer base. BGIP's product portfolio comprises a wide-range of bioscience products, which are tailored to the needs of the domestic market in India.”

The company was also in the news, with its parent company acquiring Millipore Corporation, based in Billerica, Massachusetts, US, for Rs 33,400 cr ($7.2 bn).

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X